Viking Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $201.9M | $26.4M |
| FY2022 | — | $145.3M | $36.6M |
| FY2023 | — | $348.4M | $55.5M |
| FY2024 | — | $880.3M | $26.7M |
| FY2025 | — | $639.1M | $165.8M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $201.9M | $26.4M |
| FY2022 | — | $145.3M | $36.6M |
| FY2023 | — | $348.4M | $55.5M |
| FY2024 | — | $880.3M | $26.7M |
| FY2025 | — | $639.1M | $165.8M |